Market Size of Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Industry
Study Period | 2019- 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Market Size (2024) | USD 124.32 Million |
Market Size (2029) | USD 175.28 Million |
CAGR (2024 - 2029) | 7.26 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Analysis
The Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is estimated at USD 124.32 million in 2024, and is expected to reach USD 175.28 million by 2029, growing at a CAGR of 7.26% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes' composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.
73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.
The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Industry Segmentation
GLP-1 receptor agonists are a non-insulin medication combined with diet and exercise to help treat type 2 diabetes. The Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is segmented into drugs (Dulaglutide (Trulicity), Exenatide (Byetta and Bydureon), Liraglutide (Victoza), Lixisenatide (Lyxumia), and Semaglutide (Ozempic)), and geography (Saudi Arabia, Egypt, Iran, South Africa, Oman, and rest of Middle East and Africa). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the Table of Contents.
Drugs | ||||
| ||||
| ||||
| ||||
| ||||
|
Geography | |
Saudi Arabia | |
Egypt | |
Iran | |
South Africa | |
Oman | |
Rest of Middle East and Africa |
Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Size Summary
The Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market is poised for significant growth, driven by the rising prevalence of diabetes and obesity in the region. This market is characterized by the increasing adoption of GLP-1 receptor agonists, which are effective in managing type 2 diabetes and offer additional benefits such as weight loss and cardiovascular protection. The COVID-19 pandemic has further underscored the importance of these medications, as individuals with diabetes are at a higher risk of severe complications. The market is supported by the presence of major pharmaceutical companies like Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca, which are actively involved in the development and distribution of these therapies. Regulatory approvals and strategic collaborations, such as those seen with Gulf Pharmaceutical Industries and Hangzhou Zhongmei Huadong Pharmaceutical Co., are enhancing the availability of GLP-1 agonists across the region.
The market landscape is marked by a consolidated structure, with key players holding significant shares and continuously innovating to meet the growing demand. The UAE and Saudi Arabia are notable markets within the region, with Saudi Arabia experiencing a substantial increase in diabetes prevalence. Government initiatives and healthcare policies are being implemented to address the diabetes epidemic, focusing on lifestyle modifications and improved healthcare access. The approval of new therapies, such as Eli Lilly's Mounjaro, and the ongoing research into long-acting formulations like Hanmi Pharmaceutical's efpeglenatide, are expected to drive market expansion. As the region grapples with lifestyle-related diseases, the GLP-1 agonists market is anticipated to grow, supported by both clinical advancements and strategic healthcare initiatives.
Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drugs
-
2.1.1 Dulaglutide
-
2.1.1.1 Trulicity
-
-
2.1.2 Exenatide
-
2.1.2.1 Byetta
-
2.1.2.2 Bydureon
-
-
2.1.3 Liraglutide
-
2.1.3.1 Victoza
-
-
2.1.4 Lixisenatide
-
2.1.4.1 Lyxumia
-
-
2.1.5 Semaglutide
-
2.1.5.1 Ozempic
-
-
-
2.2 Geography
-
2.2.1 Saudi Arabia
-
2.2.2 Egypt
-
2.2.3 Iran
-
2.2.4 South Africa
-
2.2.5 Oman
-
2.2.6 Rest of Middle East and Africa
-
-
Middle East And Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Size FAQs
How big is the Middle East And Africa Glucagon-like Peptide-1 Agonists Market?
The Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 124.32 million in 2024 and grow at a CAGR of 7.26% to reach USD 175.28 million by 2029.
What is the current Middle East And Africa Glucagon-like Peptide-1 Agonists Market size?
In 2024, the Middle East And Africa Glucagon-like Peptide-1 Agonists Market size is expected to reach USD 124.32 million.
Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Report Snapshots
- Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Size
- Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Share
- Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Market Trends
- Middle East and Africa Glucagon-like Peptide-1 (GLP-1) Agonists Companies